Form D · Other Technology
Pluto Biosciences, Inc.
Denver, CO · CIK 0001877480
Offering snapshot reported May 5, 2025 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 21, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 5, 2025 | Initial | $3,000,000 | No comparison | 5 | SEC filing |
| May 15, 2023 | Initial | $3,704,373 | No comparison | 14 | SEC filing |
| Aug 17, 2021 | Initial | $1,006,975 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-545201
Source: Form D, filed May 5, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mike Dodd | Director |
| Christopher Glode | Director |
| Rani K. Powers | Director, Executive |
| Dalton Wright | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
3575 Ringsby Court Suite 414
Denver, CO, 80216
Denver, CO, 80216